Employers can fund weight loss drugs at a fixed cap instead of open-ended coverage. Large employer coverage fell from 72% to 60% this year, per one survey.
Recap by typeshit. Full story at Insurance Business.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Roche is putting $100 million behind an obesity target that looks promising but already has rivals. The shared headline doesn't name the target.
Biomea Fusion has released early-stage trial results for BMF-650. Details are in the company's announcement.
Loading…